A
CLDX icon

Allianz’s Celldex Therapeutics CLDX Stock Holding History

Allianz’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,400
Closed -$51.8K – 395
2024
Q2 		$51.8K Hold
1,400
– – ﹤0.01% 394
2024
Q1 		$58.8K Buy
+1,400
New +$57.5K ﹤0.01% 397

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Allianz's CLDX Position: Q3 2024 in Review

Allianz sold out of Celldex Therapeutics (CLDX) in Q3 2024, closing a stake of 1,400 shares — an estimated $51.8K sold.

Allianz first reported a position in CLDX in Q1 2024 and held it in 2 quarters. The position peaked at $58.8K in Q1 2024. 176 funds tracked by Wall St. Rank hold CLDX as of Q3 2024.

  • Allianz reported no remaining Celldex Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Allianz sold 1,400 Celldex Therapeutics shares in Q3 2024, an estimated $51.8K.
  • Allianz first reported a position in Celldex Therapeutics in Q1 2024 and held it in 2 quarters.
  • Allianz's Celldex Therapeutics position peaked at $58.8K in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2024.

Based on Allianz's 13F filing for Q3 2024, filed 12 May 2025.